Earnings Review · 10 August 2026
JBS Had a Strong Quarter. Why a Values-Conscious Book Still Steps Aside.
The print
Revenue $21.61B vs $1.71 expected.
Did the flow confirm the move?
Money has been flowing IN underneath a flat-to-lower price: quiet accumulation, the kind of positioning that tends to show up before a name moves, not after.
Give the business its due
The business itself is genuinely strong: revenue growing about 11%, net margins near 2%, a narrow competitive moat.
The valuation lens
Our framework labels the valuation n/a. Fair value lands near $20 against a $14 share price, a margin of safety of about 48%. The trailing multiple sits around 8 times earnings, which only makes sense if the growth holds.
The ethical lens, our differentiator
Fails the principled screen, Debt ratio. A strong business is not the same as a suitable one; for a values-conscious book this is a do-not-chase regardless of the print.
The compliant alternative
If the theme is what draws you, Usana Health Sciences Inc (USNA) sits in the same industry (Packaged Foods) and clears our principled screen, the place to look instead of chasing a name that does not.
The verdict for a values-conscious investor
A beat-and-raise does not change the screen. This is a great company you can admire without owning, protection first. We do not confuse a strong quarter with a suitable holding.
This is analysis, not financial advice. Always manage your risk.
